查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370897

Alpha-1 抗胰蛋白酶缺乏症市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、给药途径、配销通路、地区、竞争细分。

Alpha-1 Antitrypsin Deficiency Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Route Of Administration, By Distribution Channel, By Region, By Competition.
出版日期: | 出版商: TechSci Research | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球 Alpha-1 抗胰蛋白酶缺乏症市场估值达到 18,0936 万美元，在整个预测期内有望实现令人印象深刻的成长，预计到 2028 年复合年增长率 (CAGR) 为 6.49%，预计到2028 年将达到26.2718 亿美元。Alpha-1 抗胰蛋白酶缺乏症（Alpha-1 抗胰蛋白酶缺乏症）是一种影响肺部和肝臟的罕见遗传性疾病。它是由于 α-1 抗胰蛋白酶蛋白水平不足而引起的，导致更容易患肺病和肝病。儘管 Alpha-1 抗胰蛋白酶缺乏症很罕见，但它会严重影响患者的生活品质和医疗保健系统。随着研究的进步和意识的传播，Alpha-1 抗胰蛋白酶缺乏症市场正在发生变化，挑战与机会并存。

Alpha-1 抗胰蛋白酶是一种肝臟产生的蛋白质，对于保护肺部免受酵素引起的发炎损伤至关重要。在 Alpha-1 抗胰蛋白酶缺乏症的情况下，基因突变会导致错误折迭的蛋白质在肝臟中积累，而不是释放到血液中。这种缺陷会增加对慢性阻塞性肺病（COPD）等肺部疾病和肝硬化等肝臟疾病的易感性。

市场概况
预测期 2024-2028
2022 年市场规模 180936万美元
2028 年市场规模 262718万美元
2023-2028 年复合年增长率 6.49%
成长最快的细分市场 Alpha-1 蛋白酶抑制剂
最大的市场 北美洲

政府措施和研究经费推动了全球 Alpha-1 抗胰蛋白酶缺乏症市场。随着对 Alpha-1 抗胰蛋白酶缺乏症等罕见疾病的认识不断提高，支持研究、诊断和治疗开发的政策和计划也越来越受到关注。研究计画、临床试验和患者支持的资金吸引了製药公司和研究人员，加速了进步。

主要市场驱动因素

  • 1.增加患者基础：由于患者人数的增加，全球 Alpha-1 抗胰蛋白酶缺乏症市场大幅成长。虽然是一种罕见的遗传性疾病，但随着意识和诊断精确度的提高，病例报告不足和误诊导致了更大的目标群体。病例增加促使製药和研究重点增加，推动市场扩张。
  • 2.监管支持：研究人员、临床医生、患者、倡导团体和製药公司之间的合作努力促进了 Alpha-1 抗胰蛋白酶缺乏症的理解、治疗和患者护理方面的进步。跨机构联盟、药学学术合作和数位资料共享改变了传统的研究和治疗方法，促进了进步。

主要市场挑战

  • 1.诊断不足与误诊：Alpha-1抗胰蛋白酶缺乏症市场的一个重大挑战在于其诊断不足和误诊。许多患者仍未被诊断或误诊为其他肺部疾病，延误了准确的治疗策略。
  • 2.认识有限：Alpha-1抗胰蛋白酶缺乏症的罕见性导致公众和医疗保健专业人员的认识有限，导致诊断延迟和支持不足。
  • 3.复杂的治疗：由于 Alpha-1 抗胰蛋白酶缺乏症的遗传性质和双肺肝併发症，开发有效的治疗方法非常复杂，因此需要同时解决这两个方面的治疗方法。

主要市场趋势

  • 1.技术进步：基因筛检的技术突破能够实现早期 Alpha-1 抗胰蛋白酶缺乏症检测，从而实现主动干预。精准医学根据基因组成客製化治疗方案，提高疗效。基因疗法和编辑探索治疗遗传根源，有可能改变疾病管理。
  • 2.协作努力：跨学科合作加速了对 Alpha-1 抗胰蛋白酶缺乏症的理解和管理。研究联盟、製药学术伙伴关係和患者倡导团体加速研究、创新和治疗开发。

细分市场洞察

  • 1.产品：2022年，Alpha-1蛋白酶抑制剂领域引领Alpha-1抗胰蛋白酶缺乏症市场，预计将继续其成长轨迹。透过酵素替代疗法 (ERT) 补充 A1PI 水平不足有助于缓解症状，减缓肺损伤进展。
  • 2.配销通路：2022年，在Alpha-1抗胰蛋白酶缺乏症患者所需的综合护理的推动下，医院药房主导了市场，涉及各个学科的专家。

区域洞察

北美：该研究中心拥有领先的机构、研究中心和製药公司，推动 Alpha-1 抗胰蛋白酶缺乏症的了解、诊断和治疗。临床试验主要在这里进行，可以儘早获得新疗法并巩固北美的市场领导地位。该地区的可支配收入、医疗保健支出和覆盖范围巩固了市场主导地位。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球 Alpha-1 抗胰蛋白酶缺乏症市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产物（Alpha-1 蛋白酶抑制剂、支气管扩张剂、皮质类固醇、氧气治疗）
    • 依给药途径（注射、口服、吸入）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司划分（前 5 名市场参与者的股份）
  • 市场地图
    • 按产品分类
    • 依给药途径
    • 按配销通路
    • 按地区

第 6 章：北美 Alpha-1 抗胰蛋白酶缺乏症市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依给药途径
    • 按配销通路
    • 按国家/地区

第 7 章：欧洲 Alpha-1 抗胰蛋白酶缺乏症市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依给药途径
    • 按配销通路
    • 按国家/地区

第 8 章：亚太地区 Alpha-1 抗胰蛋白酶缺乏症市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依给药途径
    • 按配销通路
    • 按国家/地区

第 9 章：南美洲 Alpha-1 抗胰蛋白酶缺乏症市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区

第 10 章：中东与非洲 Alpha-1 抗胰蛋白酶缺乏症市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第13章：竞争格局

  • 夏尔公司
  • 葛兰素史克公司
  • CSL贝林
  • 阿斯特捷利康公司
  • 格里福斯公司
  • 梯瓦製药工业公司
  • 勃林格殷格翰国际股份有限公司
  • 镰田製药
  • 辉瑞公司
  • 百特国际公司

第 14 章：策略建议

第 15 章：关于我们与免责声明

简介目录
Product Code: 15894

The Global Alpha-1 Antitrypsin Deficiency Disease Market reached a valuation of USD 1809.36 Million in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.49% up to 2028 and expected to reach USD 2627.18 Million by 2028. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is an uncommon genetic disorder impacting the lungs and liver. It arises due to insufficient levels of the alpha-1 antitrypsin protein, resulting in an elevated vulnerability to lung and liver diseases. Despite its rarity, Alpha-1 Antitrypsin Deficiency Disease significantly affects patients' quality of life and healthcare systems. As research advances and awareness spreads, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing changes, presenting both challenges and opportunities.

Alpha-1 antitrypsin is a liver-produced protein pivotal in safeguarding lungs against inflammation-induced damage from enzymes. In cases of Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to misfolded protein accumulation in the liver instead of release into the bloodstream. This deficiency heightens susceptibility to lung ailments like chronic obstructive pulmonary disease (COPD) and liver conditions such as cirrhosis.

While the Alpha-1 Antitrypsin Deficiency Disease market is relatively compact due to the disease's rarity, it garners attention from researchers, pharmaceutical firms, and healthcare providers. Notable players in diagnostics, treatments, and therapies concentrate on addressing the underlying deficiency and managing linked complications. Biotechnology, genomics, and personalized medicine progress yield targeted, effective treatments for Alpha-1 Antitrypsin Deficiency Disease, potentially revolutionizing patient outcomes.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1809.36 Million
Market Size 2028USD 2627.18 Million
CAGR 2023-20286.49%
Fastest Growing SegmentAlpha-1 Proteinase Inhibitor
Largest MarketNorth America

Government initiatives and research funding propel the global Alpha-1 Antitrypsin Deficiency Disease market. As rare disease awareness, like Alpha-1 Antitrypsin Deficiency Disease, heightens, policies and programs supporting research, diagnosis, and treatment development gain traction. Funds for research projects, clinical trials, and patient support captivate pharmaceutical companies and researchers, spurring accelerated advancements.

Primary Market Drivers

  • 1. Increasing Patient Base: The Global Alpha-1 Antitrypsin Deficiency Disease Market witnesses substantial growth due to a rising patient population. Though a rare genetic disorder, underreported cases and misdiagnoses result in a larger target group as awareness and diagnostic precision improve. Heightened cases prompt increased pharmaceutical and research focus, driving market expansion.
  • 2. Regulatory Backing: Collaborative efforts among researchers, clinicians, patients, advocacy groups, and pharmaceutical firms catalyze advancements in Alpha-1 Antitrypsin Deficiency Disease understanding, treatment, and patient care. Cross-institutional consortia, pharmaceutical-academic collaborations, and digital data sharing transform traditional research and treatment approaches, fostering progress.

Key Market Challenges

  • 1. Underdiagnosis and Misdiagnosis: A substantial challenge in the Alpha-1 Antitrypsin Deficiency Disease market lies in its underdiagnosis and misdiagnosis. Many patients remain undiagnosed or misdiagnosed as other lung conditions, delaying accurate treatment strategies.
  • 2. Limited Awareness: The rarity of Alpha-1 Antitrypsin Deficiency Disease results in limited awareness among the public and healthcare professionals, causing delayed diagnosis and insufficient support.
  • 3. Complex Treatment: Developing effective treatments for Alpha-1 Antitrypsin Deficiency Disease is intricate due to its genetic nature and dual lung-liver complications, necessitating therapies addressing both aspects.

Key Market Trends

  • 1. Technological Advancements: Technological breakthroughs in genetic screening enable early Alpha-1 Antitrypsin Deficiency Disease detection, allowing proactive intervention. Precision medicine tailors treatment based on genetic makeup, enhancing efficacy. Gene therapies and editing explore treating the genetic root, potentially transforming disease management.
  • 2. Collaborative Efforts: Cross-disciplinary collaborations accelerate Alpha-1 Antitrypsin Deficiency Disease understanding and management. Research consortia, pharmaceutical-academic partnerships, and patient advocacy groups expedite research, innovation, and treatment development.

Segment Insights

  • 1. Product: In 2022, the Alpha-1 Proteinase Inhibitor segment led the Alpha-1 Antitrypsin Deficiency Disease market and is expected to continue its growth trajectory. Replenishing deficient A1PI levels through enzyme replacement therapy (ERT) helps alleviate symptoms, slowing lung damage progression.
  • 2. Distribution Channel: In 2022, Hospital pharmacies dominated the market, driven by the comprehensive care Alpha-1 Antitrypsin Deficiency Disease patients require, involving specialists from various disciplines.

Regional Insights

North America: This research hub boasts leading institutions, research centers, and pharmaceutical companies, propelling Alpha-1 Antitrypsin Deficiency Disease understanding, diagnostics, and treatments. Clinical trials predominantly occur here, giving early access to new therapies and consolidating North America's market leadership. The region's disposable income, healthcare spending, and coverage bolster market dominance.

Key Market Players

  • Shire plc
  • GlaxoSmithKline plc
  • CSL Behring
  • AstraZeneca Plc.
  • Grifols S.A.
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim International GmbH
  • Kamada Pharmaceuticals
  • Pfizer Inc.
  • Baxter International Inc.

Report Scope:

  • In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

  • Alpha-1 Proteinase Inhibitor
  • Bronchodilato
  • Corticosteroid
  • Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

  • Injection
  • Oral
  • Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

  • Hospitals Pharmacy
  • Retail Pharmacies
  • Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

  • Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
    • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
    • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Route of Administration
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Product
        • 6.2.4.1.2.2. By Route of Administration
        • 6.2.4.1.2.3. By Distribution Channel (
      • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Product
        • 6.2.4.2.2.2. By Route of Administration
        • 6.2.4.2.2.3. By Distribution Channel
      • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Test
        • 6.2.4.3.2.2. By Route of Administration
        • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Route of Administration
        • 7.2.4.1.2.3. By Distribution Channel
      • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Route of Administration
        • 7.2.4.2.2.3. By Distribution Channel
      • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Route of Administration
        • 7.2.4.3.2.3. By Distribution Channel
      • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Route of Administration
        • 7.2.4.4.2.3. By Distribution Channel
      • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Route of Administration
        • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Product
        • 8.2.4.1.2.2. By Route of Administration
        • 8.2.4.1.2.3. By Distribution Channel
      • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Product
        • 8.2.4.2.2.2. By Route of Administration
        • 8.2.4.2.2.3. By Distribution Channel
      • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Product
        • 8.2.4.3.2.2. By Route of Administration
        • 8.2.4.3.2.3. By Distribution Channel
      • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Product
        • 8.2.4.4.2.2. By Route of Administration
        • 8.2.4.4.2.3. By Distribution Channel
      • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Product
        • 8.2.4.5.2.2. By Route of Administration
        • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Route of Administration
        • 9.2.4.1.2.3. By Distribution Channel
      • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Route of Administration
        • 9.2.4.2.2.3. By Distribution Channel
      • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Route of Administration
        • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Product
        • 10.2.4.1.2.2. By Route of Administration
        • 10.2.4.1.2.3. By Distribution Channel
      • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Product
        • 10.2.4.2.2.2. By Route of Administration
        • 10.2.4.2.2.3. By Distribution Channel
      • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Product
        • 10.2.4.3.2.2. By Route of Administration
        • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Shire plc
  • 13.2. GlaxoSmithKline plc
  • 13.3. CSL Behring
  • 13.4. AstraZeneca Plc.
  • 13.5. Grifols S.A.
  • 13.6. Teva Pharmaceutical Industries
  • 13.7. Boehringer Ingelheim International GmbH
  • 13.8. Kamada Pharmaceuticals
  • 13.9. Pfizer Inc.
  • 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer